# Stroke

## Overview

Stroke is a cerebrovascular disease characterized by the sudden onset of focal neurological deficits due to interruption of blood flow to the brain. It is the leading cause of disability and the second leading cause of death worldwide. Stroke is a medical emergency requiring immediate intervention to minimize brain damage and improve outcomes.

### Definition and Classification
- **Stroke**: Acute focal neurological deficit lasting >24 hours or leading to death
- **Transient ischemic attack (TIA)**: Temporary focal neurological deficit lasting <24 hours
- **Types**: Ischemic stroke (87%), hemorrhagic stroke (13%)
- **Time windows**: Critical for treatment decisions

## Types of Stroke

### Ischemic Stroke
- **Prevalence**: 85-87% of all strokes
- **Mechanism**: Reduction or cessation of cerebral blood flow
- **Subtypes**: Thrombotic, embolic, lacunar, cryptogenic
- **Reversibility**: Potential for reperfusion therapy

#### Large Vessel Occlusion
- **Arteries affected**: Internal carotid, middle cerebral, anterior cerebral arteries
- **Mechanism**: Thrombosis or embolism
- **Clinical features**: Severe neurological deficits
- **Treatment**: Mechanical thrombectomy consideration

#### Small Vessel Disease (Lacunar Strokes)
- **Size**: <15mm diameter lesions
- **Location**: Deep white matter, brainstem, basal ganglia
- **Risk factors**: Hypertension, diabetes
- **Syndromes**: Pure motor, pure sensory, ataxic hemiparesis

#### Cardioembolic Stroke
- **Sources**: Atrial fibrillation, valvular disease, heart failure
- **Characteristics**: Sudden onset, cortical involvement
- **Risk**: High recurrence without anticoagulation
- **Investigation**: Cardiac monitoring, echocardiography

### Hemorrhagic Stroke

#### Intracerebral Hemorrhage (ICH)
- **Prevalence**: 10-15% of strokes
- **Locations**: Basal ganglia, thalamus, brainstem, cerebellum, lobar
- **Risk factors**: Hypertension, anticoagulation, amyloid angiopathy
- **Prognosis**: Higher mortality than ischemic stroke

#### Subarachnoid Hemorrhage (SAH)
- **Prevalence**: 3-5% of strokes
- **Causes**: Aneurysmal (85%), non-aneurysmal (15%)
- **Presentation**: "Worst headache of life", nuchal rigidity
- **Complications**: Rebleeding, vasospasm, hydrocephalus

## Pathophysiology

### Ischemic Cascade
- **Energy failure**: ATP depletion within minutes
- **Ion pump failure**: Cellular swelling, membrane depolarization
- **Calcium influx**: Enzymatic activation, cellular damage
- **Free radical formation**: Oxidative stress and lipid peroxidation
- **Inflammation**: Cytokine release, blood-brain barrier breakdown

### Penumbra Concept
- **Core**: Irreversibly damaged tissue (CBF <10-15 mL/100g/min)
- **Penumbra**: Potentially salvageable tissue (CBF 15-20 mL/100g/min)
- **Oligemia**: Mildly hypoperfused but viable tissue
- **Time dependency**: Penumbra evolves to core over time

### Cerebral Blood Flow Regulation
- **Autoregulation**: Maintenance of CBF despite pressure changes
- **Collateral circulation**: Alternative blood flow pathways
- **Metabolic coupling**: CBF matches metabolic demands
- **Failure mechanisms**: Pressure-passive circulation in stroke

### Hemorrhagic Mechanisms

#### Primary Brain Injury
- **Mass effect**: Direct tissue compression
- **Increased intracranial pressure**: Global cerebral hypoperfusion
- **Hydrocephalus**: CSF flow obstruction
- **Herniation**: Brainstem compression

#### Secondary Brain Injury
- **Perihematomal edema**: Inflammatory response
- **Hematoma expansion**: Progressive bleeding
- **Seizures**: Electrical instability
- **Fever**: Increased metabolic demands

## Risk Factors

### Non-Modifiable Risk Factors
- **Age**: Risk doubles every decade after 55
- **Sex**: Slightly higher in men, but women have worse outcomes
- **Race/ethnicity**: Higher risk in African Americans, Hispanics
- **Genetics**: Family history, specific genetic variants

### Modifiable Risk Factors

#### Major Risk Factors
- **Hypertension**: Most important modifiable risk factor (RR 3-5)
- **Atrial fibrillation**: 5-fold increased risk, especially with CHADS2-VASc
- **Diabetes mellitus**: 2-3-fold increased risk
- **Smoking**: 2-fold increased risk, dose-dependent
- **Hyperlipidemia**: Modest increase, especially with other factors

#### Other Risk Factors
- **Carotid stenosis**: Significant if >70% stenosis
- **Heart disease**: Coronary artery disease, heart failure
- **Obesity**: Increased risk, especially central obesity
- **Physical inactivity**: Sedentary lifestyle
- **Excessive alcohol**: >2 drinks/day increases risk
- **Drug use**: Cocaine, amphetamines

## Clinical Presentation

### General Principles
- **Sudden onset**: Maximal deficit at onset or stuttering progression
- **Focal deficits**: Correspond to vascular territories
- **Negative symptoms**: Loss of function (vs. positive symptoms)
- **Variability**: Depends on location, size, and etiology

### Anterior Circulation Syndromes

#### Middle Cerebral Artery (MCA)
- **Motor**: Contralateral hemiparesis (face and arm > leg)
- **Sensory**: Contralateral hemisensory loss
- **Language**: Aphasia (dominant hemisphere)
- **Spatial**: Neglect (non-dominant hemisphere)
- **Visual**: Contralateral homonymous hemianopia

#### Anterior Cerebral Artery (ACA)
- **Motor**: Contralateral leg weakness > arm
- **Behavioral**: Abulia, personality changes
- **Urinary**: Incontinence
- **Gait**: Apraxia

#### Internal Carotid Artery (ICA)
- **Complete occlusion**: MCA + ACA territory involvement
- **Ophthalmic artery**: Transient monocular blindness (amaurosis fugax)
- **Watershed**: Between ACA-MCA or MCA-PCA territories

### Posterior Circulation Syndromes

#### Posterior Cerebral Artery (PCA)
- **Visual**: Contralateral homonymous hemianopia with macular sparing
- **Memory**: Amnesia (if bilateral or dominant hemisphere)
- **Reading**: Alexia without agraphia (dominant hemisphere)
- **Behavioral**: Agitation, hallucinations

#### Vertebrobasilar System
- **Brainstem**: Cranial nerve palsies, crossed sensorimotor deficits
- **Cerebellar**: Ataxia, dysmetria, nystagmus
- **Consciousness**: Coma (if bilateral or reticular formation)
- **Breathing**: Respiratory dysfunction

### Lacunar Syndromes
- **Pure motor hemiparesis**: Internal capsule, corona radiata
- **Pure sensory stroke**: Thalamus
- **Ataxic hemiparesis**: Pons, internal capsule
- **Dysarthria-clumsy hand**: Pons, internal capsule
- **Mixed sensorimotor**: Thalamus, internal capsule

### Hemorrhagic Presentations

#### Intracerebral Hemorrhage
- **Onset**: Often during activity, progressive worsening
- **Headache**: Severe, especially if large or intraventricular extension
- **Nausea/vomiting**: Due to increased intracranial pressure
- **Altered consciousness**: Related to location and size

#### Subarachnoid Hemorrhage
- **Headache**: Sudden, severe ("thunderclap")
- **Meningeal signs**: Neck stiffness, photophobia
- **Focal deficits**: May be absent initially
- **Seizures**: 10-15% at presentation

### Time Course Patterns
- **Sudden onset**: Embolic stroke, hemorrhage
- **Stuttering**: Thrombotic stroke, crescendo TIAs
- **Progressive**: Large vessel thrombosis, hemorrhage expansion
- **Fluctuating**: Hemodynamic compromise, seizures

## Diagnosis

### Initial Assessment

#### Clinical History
- **Time of onset**: Last known normal time
- **Symptom progression**: Sudden vs. gradual
- **Activity at onset**: Rest, exertion, specific activities
- **Associated symptoms**: Headache, seizures, loss of consciousness
- **Risk factors**: Previous stroke, medications, family history

#### Physical Examination
- **Vital signs**: Blood pressure, heart rate, temperature, oxygen saturation
- **General**: Signs of trauma, cardiac arrhythmias
- **Neurological**: Comprehensive assessment using standardized scales

### Stroke Scales

#### National Institutes of Health Stroke Scale (NIHSS)
- **Components**: 11 items assessing consciousness, vision, motor, sensory, language
- **Scoring**: 0-42 points (higher scores = more severe)
- **Uses**: Severity assessment, treatment decisions, outcome prediction
- **Reliability**: Validated, standardized administration

#### Other Scales
- **Modified Rankin Scale**: Functional outcome assessment
- **Barthel Index**: Activities of daily living
- **Glasgow Coma Scale**: Consciousness level

### Neuroimaging

#### Computed Tomography (CT)
- **Non-contrast CT**: First-line imaging, excludes hemorrhage
- **Sensitivity**: Poor for early ischemia (<6 hours)
- **Advantages**: Fast, widely available, detects hemorrhage
- **Findings**: Hypodensity, mass effect, hemorrhage

#### CT Angiography (CTA)
- **Indications**: Large vessel occlusion assessment
- **Advantages**: Fast, widely available
- **Information**: Vessel anatomy, collateral circulation
- **Limitations**: Contrast exposure, artifact

#### CT Perfusion (CTP)
- **Parameters**: Cerebral blood flow, volume, mean transit time
- **Uses**: Penumbra assessment, treatment selection
- **Limitations**: Radiation, contrast, processing time

#### Magnetic Resonance Imaging (MRI)
- **DWI**: Detects acute ischemia within minutes
- **FLAIR**: Subacute changes, hemorrhage
- **T2***: Hemorrhage, microbleeds
- **Advantages**: Superior sensitivity, no radiation
- **Limitations**: Time, availability, contraindications

#### MR Angiography (MRA)
- **Time-of-flight**: Non-contrast vessel imaging
- **Contrast-enhanced**: Better resolution
- **Advantages**: No radiation, detailed anatomy
- **Limitations**: Overestimation of stenosis, flow artifacts

### Laboratory Studies
- **Complete blood count**: Anemia, thrombocytopenia, polycythemia
- **Basic metabolic panel**: Glucose, electrolytes, renal function
- **Coagulation studies**: PT/INR, aPTT, platelets
- **Cardiac markers**: If suspected myocardial infarction
- **Toxicology**: If drug use suspected

### Cardiac Evaluation
- **Electrocardiogram**: Atrial fibrillation, myocardial infarction
- **Echocardiogram**: Valve disease, wall motion abnormalities, thrombus
- **Holter monitor**: Paroxysmal atrial fibrillation
- **Bubble study**: Patent foramen ovale

### Vascular Imaging
- **Carotid ultrasound**: Extracranial carotid stenosis
- **Transcranial Doppler**: Intracranial vessel assessment
- **Digital subtraction angiography**: Gold standard for vessel imaging

## Treatment

### Acute Management Principles
- **Time-sensitive**: "Time is brain" - rapid intervention crucial
- **Multidisciplinary**: Stroke team approach
- **Protocols**: Standardized pathways for efficiency
- **Monitoring**: Continuous assessment for complications

### Emergency Department Management

#### Initial Stabilization
- **Airway**: Protect if altered consciousness
- **Breathing**: Supplemental oxygen if hypoxic (SpO2 <94%)
- **Circulation**: IV access, cardiac monitoring
- **Disability**: Neurological assessment, glucose check
- **Exposure**: Complete examination, temperature control

#### Blood Pressure Management
- **Ischemic stroke**: Permissive hypertension (SBP <220, DBP <120)
- **ICH**: Aggressive reduction (SBP 140-160 mmHg target)
- **tPA candidate**: SBP <185, DBP <110 mmHg before treatment
- **Agents**: Labetalol, nicardipine, clevidipine

### Reperfusion Therapy

#### Intravenous Thrombolysis
- **Agent**: Alteplase (tPA) 0.9 mg/kg (max 90 mg)
- **Time window**: 0-4.5 hours from symptom onset
- **Inclusion criteria**: Disabling stroke, measurable deficit
- **Exclusion criteria**: Recent surgery, active bleeding, severe comorbidities

##### Extended Window Criteria
- **Wake-up stroke**: MRI-guided selection (DWI-FLAIR mismatch)
- **4.5-9 hours**: Clinical-imaging mismatch on perfusion
- **Selection tools**: DAWN, DEFUSE-3 criteria

#### Mechanical Thrombectomy
- **Indications**: Large vessel occlusion, NIHSS ≥ 6
- **Time window**: 0-24 hours (with imaging selection)
- **Technique**: Stent retrievers, aspiration catheters
- **Centers**: Requires specialized neurointerventional capabilities

##### Thrombectomy Criteria
- **Vessel occlusion**: ICA, M1, M2, basilar artery
- **Collateral circulation**: Good collaterals favor intervention
- **Imaging selection**: Core <70 mL, mismatch ratio >1.8
- **Functional status**: Pre-stroke mRS 0-1

### Hemorrhagic Stroke Management

#### Intracerebral Hemorrhage
- **Blood pressure**: Target SBP 140-160 mmHg acutely
- **Coagulopathy reversal**: Vitamin K, PCC, fresh frozen plasma
- **ICP management**: Head of bed elevation, osmotic agents
- **Surgical evacuation**: Selected cases with accessible hematomas

#### Subarachnoid Hemorrhage
- **Aneurysm securing**: Surgical clipping or endovascular coiling
- **Vasospasm prevention**: Nimodipine, adequate hydration
- **Complications**: Rebleeding, hydrocephalus, seizures
- **Monitoring**: Neurological exams, transcranial Doppler

### Supportive Care

#### Medical Management
- **Glucose control**: Target 140-180 mg/dL
- **Temperature**: Fever reduction, normothermia
- **Nutrition**: Early feeding, swallow evaluation
- **DVT prophylaxis**: Sequential compression devices, heparin
- **Bladder care**: Avoid indwelling catheters

#### Neurological Monitoring
- **Frequent exams**: NIHSS every 2-4 hours initially
- **ICP monitoring**: If signs of elevated pressure
- **Seizure detection**: EEG if altered consciousness
- **Complications**: Hemorrhagic transformation, edema

### Rehabilitation
- **Early mobilization**: Within 24-48 hours if stable
- **Multidisciplinary team**: PT, OT, speech therapy
- **Goal setting**: Realistic, patient-centered objectives
- **Discharge planning**: Home vs. facility placement

## Secondary Prevention

### Antiplatelet Therapy
- **Aspirin**: 75-100 mg daily, first-line therapy
- **Clopidogrel**: 75 mg daily, alternative to aspirin
- **Dual antiplatelet**: Short-term use in high-risk patients
- **Contraindications**: Active bleeding, severe liver disease

### Anticoagulation
- **Atrial fibrillation**: Warfarin or NOACs (apixaban, rivaroxaban)
- **CHA2DS2-VASc score**: Risk stratification tool
- **Bleeding risk**: HAS-BLED score assessment
- **Timing**: Usually delayed 1-2 weeks after stroke

### Risk Factor Modification

#### Hypertension
- **Target**: <130/80 mmHg for most patients
- **Agents**: ACE inhibitors, ARBs, thiazide diuretics
- **Combination therapy**: Often required
- **Monitoring**: Home blood pressure measurements

#### Diabetes
- **Target**: HbA1c <7% for most patients
- **Agents**: Metformin first-line, GLP-1 agonists
- **Complications**: Retinopathy, nephropathy screening
- **Lifestyle**: Diet, exercise, weight management

#### Hyperlipidemia
- **Target**: LDL <70 mg/dL for high-risk patients
- **Statins**: High-intensity preferred (atorvastatin, rosuvastatin)
- **Ezetimibe**: Add-on therapy if needed
- **PCSK9 inhibitors**: For very high-risk patients

#### Lifestyle Modifications
- **Smoking cessation**: Counseling, pharmacotherapy
- **Exercise**: 150 minutes moderate activity weekly
- **Diet**: Mediterranean or DASH diet patterns
- **Weight management**: BMI 18.5-24.9 kg/m²
- **Alcohol**: Moderate consumption or avoidance

### Carotid Intervention
- **Carotid endarterectomy**: 70-99% symptomatic stenosis
- **Carotid stenting**: High surgical risk patients
- **Timing**: Within 2 weeks of symptoms
- **Asymptomatic stenosis**: >80% stenosis, selected patients

## Complications

### Acute Complications

#### Neurological
- **Cerebral edema**: Peak 24-72 hours, mass effect
- **Hemorrhagic transformation**: 5-15% of ischemic strokes
- **Seizures**: 5-10%, more common with cortical involvement
- **Increased ICP**: Herniation risk, requires monitoring

#### Medical
- **Pneumonia**: Aspiration, immobility
- **Deep vein thrombosis**: Immobilization, hemiparesis
- **Urinary tract infection**: Catheter-associated
- **Cardiac complications**: Arrhythmias, myocardial infarction

### Chronic Complications

#### Functional Impairments
- **Motor**: Hemiparesis, spasticity, pain
- **Sensory**: Numbness, central pain syndrome
- **Cognitive**: Executive dysfunction, memory impairment
- **Language**: Aphasia, dysarthria
- **Visual**: Hemianopia, neglect

#### Psychosocial
- **Depression**: 30-50% of stroke survivors
- **Anxiety**: Social isolation, fear of recurrence
- **Caregiver burden**: Family impact, support needs
- **Return to work**: Often limited, vocational rehabilitation

## Prognosis

### Factors Affecting Outcome

#### Patient Factors
- **Age**: Worse outcomes with advancing age
- **Comorbidities**: Diabetes, heart disease impact recovery
- **Pre-stroke function**: Baseline disability affects potential
- **Social support**: Family, resources influence rehabilitation

#### Stroke Factors
- **Severity**: NIHSS score correlates with outcome
- **Location**: Dominant hemisphere, brainstem worse prognosis
- **Size**: Larger strokes have worse outcomes
- **Type**: Hemorrhagic generally worse than ischemic

#### Treatment Factors
- **Time to treatment**: Earlier intervention improves outcomes
- **Reperfusion success**: Complete recanalization best
- **Rehabilitation intensity**: More therapy associated with better recovery
- **Complications**: Medical complications worsen prognosis

### Outcome Measures

#### Functional Outcomes
- **Modified Rankin Scale**: 0-6 scale (0=no symptoms, 6=death)
- **Barthel Index**: Activities of daily living
- **NIHSS**: Neurological impairment severity
- **Quality of life**: Patient-reported outcomes

#### Mortality
- **Acute**: 10-15% at 30 days
- **One year**: 20-25% mortality
- **Type differences**: ICH ~40%, ischemic ~15-20%
- **Age effect**: Higher mortality in elderly

### Recovery Patterns
- **Greatest recovery**: First 3-6 months
- **Continued improvement**: Up to 12-24 months
- **Plateau**: Most recovery complete by 6 months
- **Late changes**: Spasticity, central pain may develop

## Prevention

### Primary Prevention
- **Risk factor identification**: Screening, assessment
- **Lifestyle counseling**: Diet, exercise, smoking cessation
- **Medical management**: Hypertension, diabetes, hyperlipidemia
- **Population strategies**: Public health initiatives

### Secondary Prevention
- **Medication adherence**: Antiplatelet, anticoagulant therapy
- **Risk factor control**: Intensive management
- **Regular monitoring**: Follow-up care, assessments
- **Patient education**: Warning signs, when to seek care

### Stroke Systems of Care
- **Prehospital**: Recognition, rapid transport
- **Emergency department**: Protocols, imaging
- **Inpatient care**: Stroke units, specialized teams
- **Rehabilitation**: Acute, subacute, outpatient
- **Community**: Support groups, resources

## Key Points

- Stroke is a medical emergency requiring immediate evaluation and treatment
- Ischemic strokes (87%) and hemorrhagic strokes (13%) have different pathophysiology and treatment
- Time-sensitive reperfusion therapy can dramatically improve outcomes in selected patients
- IV thrombolysis is effective within 4.5 hours, mechanical thrombectomy up to 24 hours with imaging selection
- Secondary prevention focuses on antiplatelet/anticoagulant therapy and risk factor modification
- Stroke systems of care and multidisciplinary teams optimize patient outcomes
- Rehabilitation should begin early and continue throughout the recovery process
- Complications can be minimized with appropriate monitoring and preventive care
- Functional outcomes depend on stroke severity, location, treatment, and rehabilitation
- Public health efforts for prevention and awareness are crucial for reducing stroke burden

## References

1. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2019;50:e344-418.
2. Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46:2032-2060.
3. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data. Lancet. 2016;387:1723-1731.